Nichi-Iko Delays US Infliximab Amid Coronavirus Outbreak

As Japanese Company Trains Focus On Bevacizumab

 
• By Dean Rudge
  
Delayed
Nichi-Iko's ambitions for the US infliximab market have been pushed back • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business